STOXPO
  • Latest News
  • Technology
    • Software
    • Semiconductors
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions
No Result
View All Result
  • Latest News
  • Technology
    • Software
    • Semiconductors
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions
No Result
View All Result
STOXPO
No Result
View All Result
Home Blog

BioMarin Halts Mid-Stage Trial of Voxzogo in Certain Bone Disorders

byLuca Blaumann
March 16, 2026
in Blog
Reading Time: 2 mins read
Share on TwitterShare on LinkedIn

Reports of hip joint complications prompt suspension of studies, sending shares lower

Shares of BioMarin Pharmaceutical (BMRN) fell roughly 4% after the company announced it would discontinue mid-stage clinical trials of its bone disorder treatment Voxzogo for several rare genetic conditions following reports of safety concerns among patients.

The company had been testing the therapy in individuals with Turner Syndrome, SHOX Deficiency, and Aggrecan Deficiency—three genetic disorders associated with severe short stature and, in some cases, abnormal bone development. Turner syndrome occurs in females missing part or all of one X chromosome, while SHOX deficiency is linked to a faulty gene responsible for growth regulation. Aggrecan deficiency stems from mutations affecting cartilage structure and skeletal development.

During the mid-stage studies, several patients developed a condition known as Slipped Capital Femoral Epiphysis (SCFE), a rare but serious complication in which the ball of the hip joint slips out of place from the thigh bone at the growth plate. The condition typically occurs in adolescents while bones are still developing and can lead to pain, mobility problems, and the need for surgical intervention.

Following these reports, BioMarin decided to halt the trials for those specific indications as a precautionary measure. Despite the setback, the company stated that it will continue evaluating Voxzogo in other patient populations, including individuals with Noonan Syndrome and patients experiencing unexplained forms of short stature.

Voxzogo already has an established regulatory foothold. The U.S. Food and Drug Administration approved the injectable therapy in 2021 for patients with Achondroplasia, the most common form of dwarfism.

Competition in the space has also intensified. Last month, Ascendis Pharma received FDA approval for Yuviwel, a once-weekly injection that became the second therapy authorized in the United States to treat achondroplasia.

While BioMarin’s decision highlights the challenges of developing therapies for rare genetic growth disorders, the company remains focused on advancing Voxzogo in other clinical areas where it believes the treatment may still provide meaningful benefits for patients.

You might like this article:Urgently Shares Surge After Acquisition Announcement and Strong Q4 Results

Tags: BMRNGrowthMoversNewsStock Market
Previous Post

Urgently Shares Surge After Acquisition Announcement and Strong Q4 Results

Next Post

Meta Stock Rises on $27 Billion AI Cloud Deal with Nebius

Related Posts

CoreWeave Soars After Earnings Beat as AI Cloud Demand Shows No Signs of Slowing

byLuca Blaumann
August 12, 2026
0

Revenue more than doubles, operating leverage improves, and a massive backlog highlights accelerating enterprise AI adoption CoreWeave (CRWV) shares surged...

investing

Velo3D Tops Expectations as Demand for Metal 3D Printing Accelerates

byLuca Blaumann
August 11, 2026
0

Strong revenue growth, higher bookings, and expanded manufacturing capacity position the company for continued momentum Velo3D (VELO) delivered a stronger-than-expected...

Bitcoin Slides as Middle East Tensions Trigger Crypto Selloff

byLiliana Vida
May 18, 2026
0

Risk-off sentiment sparks massive liquidations while traders monitor key support levels Bitcoin (BTC) fell to its lowest level in more...

Next Post

Meta Stock Rises on $27 Billion AI Cloud Deal with Nebius

Latest News

SELLAS Life Sciences Stock Soars 170% Following Positive Phase 3 Leukemia Vaccine Results

Qualcomm CEO Rejects AI Market Correction Fears as Company Expands Into Data Centers

D-Wave Quantum Q3 Revenue Climbs 21% as Backlog Surges Over 1,200%

CoreWeave Q3 Revenue Surges Nearly 170% to $3.66 Billion as AI Demand Accelerates

CoreWeave Earnings Preview: Why Guidance Matters More Than Q3 Results

Based on Your Interest

investing
Artificial Intelligence

D-Wave Quantum Q3 Revenue Rises 21% as Bookings Surge and Quantum Adoption Expands

November 10, 2026
Auto Manufacturers

Lucid Secures $1.75 Billion Liquidity Boost From Saudi PIF to Support Turnaround

November 10, 2026
Artificial Intelligence

KULR Technology Revenue Surges 197% in Q3 as Battery Sales Nearly Quadruple

November 10, 2026

Recommended

Aerospace & Defense

Rocket Lab Q3 Revenue Surges 73% to $268 Million, Beating Wall Street Expectations

November 9, 2026
Artificial Intelligence

IonQ Shares Climb as Company Expands Government Reach Through Carahsoft Partnership

November 9, 2026
Aerospace & Defense

AST SpaceMobile and Rakuten Launch Joint Venture Backed by $1 Billion in Japanese Government Funding

November 9, 2026
Aerospace & Defense

SpaceX Secures Reported $45 Billion AI Infrastructure Deal With Anthropic

November 9, 2026
Artificial Intelligence

IonQ Revenue Surges 336% to Record $173.8 Million as Quantum Computing Demand Accelerates

November 6, 2026
Stoxpo

Follow us on social media:

Highlights

  • SELLAS Life Sciences Stock Soars 170% Following Positive Phase 3 Leukemia Vaccine Results
  • Qualcomm CEO Rejects AI Market Correction Fears as Company Expands Into Data Centers
  • D-Wave Quantum Q3 Revenue Climbs 21% as Backlog Surges Over 1,200%
  • CoreWeave Q3 Revenue Surges Nearly 170% to $3.66 Billion as AI Demand Accelerates
  • CoreWeave Earnings Preview: Why Guidance Matters More Than Q3 Results

Category

  • Blog
  • Communication Services
    • Entertainment
    • Internet
    • Telecommunications
  • Companies
    • Large-Cap
    • Mega-Cap
    • Micro-Cap
    • Mid-Cap
    • Small-Cap
  • Consumer Cyclical
    • Auto Manufacturers
    • Casinos & Gambling
    • Ground Transportation
    • Hospitality
      • Casinp
      • Resorts & Lodging
      • Restaurants
      • Travel
        • Airlines
    • Retail
    • Textiles, Apparel & Luxury Goods
  • Consumer Defensive
    • Beverages
    • Discount Stores
    • Distributor
    • Ecommerece
    • Electrical Equipment
    • Foods
    • Household & Personal Products
    • Leisure Products
    • Tobacco
  • Contributions
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Economy
  • Energy
    • Electric
    • Oil & Gas
    • Renewables
  • Financial Services
    • Asset Management
    • Banks
    • Brokerages
    • Credit Services
    • Insurance
  • Healthcare
    • Biotechnology
    • Medical Devices
    • Pharmaceuticals
  • Industrials
    • Aerospace & Defense
    • Construction
    • Industrial Machinery
  • Materials
    • Building Materials
    • Chemicals
    • Gold
    • Mining
    • Silver
    • Steel
  • Q&A's
  • Real Estate
  • Technology
    • Artificial Intelligence
    • Computer Hardware
    • Consumer Electronics
    • Cybersecurity
    • IT Services
    • Semiconductors
    • Software
  • Utilities

Latest News

chemistry-2

SELLAS Life Sciences Stock Soars 170% Following Positive Phase 3 Leukemia Vaccine Results

November 17, 2026
semiconductor-6

Qualcomm CEO Rejects AI Market Correction Fears as Company Expands Into Data Centers

November 12, 2026

D-Wave Quantum Q3 Revenue Climbs 21% as Backlog Surges Over 1,200%

November 11, 2026
  • About
  • Privacy Policy
  • Contact

© 2024 All Rights Reserved: STOXPO.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Read More

In case of sale of your personal information, you may opt out by using the link Do Not Sell My Personal Information

Accept Cookie Settings
Cookies are small text files that can be used by websites to make a user's experience more efficient. The law states that we can store cookies on your device if they are strictly necessary for the operation of this site. For all other types of cookies we need your permission. This site uses different types of cookies. Some cookies are placed by third party services that appear on our pages.
  • Always Active
    Necessary
    Necessary cookies help make a website usable by enabling basic functions like page navigation and access to secure areas of the website. The website cannot function properly without these cookies.
  • Marketing
    Marketing cookies are used to track visitors across websites. The intention is to display ads that are relevant and engaging for the individual user and thereby more valuable for publishers and third party advertisers.
  • Analytics
    Analytics cookies help website owners to understand how visitors interact with websites by collecting and reporting information anonymously.
  • Preferences
    Preference cookies enable a website to remember information that changes the way the website behaves or looks, like your preferred language or the region that you are in.
  • Unclassified
    Unclassified cookies are cookies that we are in the process of classifying, together with the providers of individual cookies.
Cookie Settings

Do you really wish to opt-out?

No Result
View All Result
  • Latest News
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Technology
    • Software
    • Semiconductors
  • Crypto
    • Bitcoin
    • Ethereum
    • Altcoins
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions

© 2024 All Rights Reserved: STOXPO.